ClinicalTrials.gg
CompletedNCT01319240Updated Oct 2, 2015

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

A Phase 1 interventional study of insulin degludec and insulin degludec/liraglutide in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-10-02.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 103 studies testing insulin degludec in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. insulin degludec · Diabetes Mellitus.

Enrollment
91st of 103
24 · median 145
Started
2011
with 10 others
Phase 1
42 of 103
none open now
Registered
42nd of 103
by date
Lead sponsor
96 of 103
Novo Nordisk A/S

Among the 103 studies testing insulin degludec in Diabetes Mellitus, this one is the 91st largest by enrollment, is one of 11 that started in 2011, is one of 42 in phase 1, and was the 42nd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 103 studies testing insulin degludec in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing insulin degludec in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of insulin degludec and liraglutide, when administered either combined or as separate administrations.

03

Conditions studied

  • Diabetes
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • (BMI) between 20.0 and 27.0 kg/m\^2 (both inclusive)
  • Body weight between 75 kg and 90 kg (both inclusive)
  • Fasting plasma glucose below 6.1 mmol/L (110 mg/dL)

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial products or related products
  • Previous participation in this trial. Participation is defined as randomised
  • Previous participation in any other clinical trial involving other products within the last 3 months before dosing in this trial
  • Donation of any blood or plasma in the past month or in excess of 500 mL within the 3 month preceding screening (trial start) or surgery or trauma with more than 500 mL blood loss within the 3 month preceding screening
  • History of or presence of cancer, or any cardiovascular, respiratory,metabolic, renal, hepatic, gastrointestinal, endocrine, diabetes, haematological, dermatological,venereal, neurological, psychiatric diseases or other major disorders that might have impact on the trial, as judged by the Investigator (Trial Physician)
  • Clinically significant abnormal haematology, biochemistry, lipids, urinalysis or coagulation screening tests, as judged by the Investigator (Trial Physician)
  • Known hepatitis or known carrier of the surface antigen (HBsAg) or antibodies, or a positive result to the test for (human immunodeficiency virus) antibodies and antigen
  • Family or personal history of MEN2 (Multiple endocrine neoplasia syndrome type 2) or familial medullary thyroid carcinoma (FMTC)
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Supine blood pressure at screening, after resting for 5 min, outside the range of 90-140 mmHg systolic or 50-90 mmHg diastolic (excluding white-coat hypertension; therefore, if a repeated measurement on a second screening visit shows values within the range, the subject can be included in the trial) or resting heart rate outside the range of 40-90 bpm
  • Clinically significant abnormal (Electrocardiogram) at screening (trial start)
  • Significant history of alcoholism or drug/chemical abuse, or a positive result of the urine drug screen or alcohol breath test, or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 250 mL of beer or lager, one glass of wine, or 20 mL spirits)
  • Smoking more than 5 cigarettes, or the equivalent, per day and unable to refrain from smoking during the in-house periods
  • Mental incapacity or language barriers which preclude adequate understanding or cooperation,unwillingness to participate in the trial or subjects that in the opinion of Investigator (trial physician) should not participate in the trial
  • Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, and vitamins (but including mega-dose vitamin therapy, as judged by the Investigator (trial physician)) within 2 weeks before the trial
  • Any condition that would interfere with trial participation or evaluation of results, as judged by the Investigator (trial physician)
  • Subjects with a history of deep leg vein thrombosis or with frequent appearance of deep leg vein thrombosis in 1st degree relatives as judged by the Investigator (trial physician)
  • Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate methods (adequate contraceptive measures as required by local law or practice)
  • Baseline (screening) calcitonin level above or equal to 50 ng/L
  • Suffer from a life threatening disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    IDegLira

    Drug: insulin degludec/liraglutide

  • Active comparator
    IDeg

    Drug: insulin degludec

  • Active comparator
    Lira

    Drug: liraglutide

Interventions

  • Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludecStudies of Insulin degludecInsulin degludec pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

  • Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

06

What researchers measure

Primary outcomes

  1. The area under insulin degludec concentration-time curve

    Time frame: from 0-infinity hours after trial product administration

  2. The area under liraglutide concentration-time curve

    Time frame: from 0-infinity hours after trial product administration

Secondary outcomes

  1. The area under insulin degludec concentration-time curve

    Time frame: from 0-120 hours after trial product administration

  2. The area under liraglutide concentration-time curve

    Time frame: from 0-72 hours after trial product administration

  3. Maximum concentration of insulin degludec

    Time frame: from 0-120 hours after trial product administration

  4. Maximum concentration of liraglutide

    Time frame: from 0-72 hours after trial product administration

  5. Number of hypoglycaemic episodes

    Time frame: From day 0 to 7-14 days after 3rd trial product administration

07

Study locations

1 site
  • Neuss, 41460, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2011
First posted
Mar 21, 2011
Start
Mar 2011
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Oct 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01319240
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 21, 2011
Start date
Mar 2011
Primary completion
May 2011
Completion
May 2011
Last update
Oct 2, 2015

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion